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Abstract
Background: Intracoronary (IC) abciximab administration remains a promising approach
aimed to increase a drug concentration in the target area and possibly improve clinical
outcomes in the setting of ST-segment elevation myocardial infarction (STEMI). The goal of
this literature review and meta-analysis is to update available knowledge comparing IC and
intravenous (IV) abciximab administration in STEMI patients.
Methods: A total of 7 randomized clinical trials (RCTs) with a median follow-up of 3 months
were included in the meta-analysis (n = 3311). All-cause mortality was selected as the primary
end point while recurrent myocardial infarction (re-MI), target vessel revascularization (TVR)
and major bleeding complications were the secondary end points.
Results: IC abciximab did not provide any benefits in terms of all-cause mortality as compared
with IV abciximab (odds ratio [OR] 0.67; 95% confidence interval [CI] 0.34–1.34). However,
this neutral effect was driven by the AIDA STEMI trial. The IC route was associated with
a reduced rate of re-MI when compared with IV administration (OR 0.61; 95% CI 0.40–0.92)
but the difference disappeared after one of the RCTs was excluded from the analysis. Both
strategies were equal regarding TVR (OR 0.66; 95% CI 0.40–1.09) and major bleeding
complications (OR 1.18; 95% CI 0.76–1.83).
Conclusions: Our updated meta-analysis shows that the clinical superiority of IC over IV
abciximab administration in STEMI patients is no longer clear after the release of the AIDA
STEMI trial results. Further research in high-risk STEMI patients is warranted to finally
determine clinical advantages of IC vs IV abciximab administration. (Cardiol J 2012; 19, 3:
230–242)
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Introduction
Therapy with glycoprotein (GP) IIb/IIIa recep-
tor antagonist abciximab remains a widely implement-
ed adjunctive strategy aimed to improve clinical out-
comes in patients with ST-segment elevation myo-
cardial infarction (STEMI) undergoing primary
percutaneous coronary intervention (pPCI) [1–3].
Recent European guidelines on myocardial revascu-
larization advise therapy with abciximab in STEMI
patients with evidence of high intracoronary (IC)
thrombus burden (class of recommendation IIa, level
of evidence A) [1]. The standard abciximab adminis-
tration regimen includes an intravenous (IV) bolus
followed by a 12-h IV infusion. There are some theo-
retical advantages of IC abciximab administration over
the IV route supported by data from some small sin-
gle-center clinical studies in STEMI patients treated
with pPCI. However, conflicting results regarding the
effectiveness and safety of IC abciximab administra-
tion have been reported recently [4–7].
The aim of this systematic literature review and
meta-analysis of randomized clinical trials (RCTs) is
to update available knowledge comparing IC and IV
abciximab administration in STEMI patients treat-
ed with pPCI with a special focus on the problem of
inconsistency between recent reports.
A search covering the period from 1st January
1993 to 1st April 2012 was conducted by two inde-
pendent investigators using PubMed, CENTRAL,
Google Scholar and ClinicalTrials.gov databases.
Proceedings from the Scientific Sessions of the
American College of Cardiology [http://www.
acc.org], American Heart Association [http://www.
aha.org], European Society of Cardiology [http://
//www.escardio.org], Transcatheter Cardiovascular
Therapeutics [http://www.tctmd.com] and EuroPCR
[http://www.europcr.com] were also included. The
following keywords were applied: “abciximab”, “in-
tracoronary administration”, “primary PCI”, “ST-ele-
vation myocardial infarction” and “randomized trial”.
References of retrieved studies were searched ma-
nually for additional studies and reviews. No language
restrictions were applied. Although we particularly
focused on new studies [4, 7–10], long-term follow-
ups of previously completed trials [5, 6] and recent
meta-analyses [11–15], we also provide a background
for our review presenting previous findings.
Why could IC abciximab administration
possibly be superior to the IV route?
Evidence from experimental studies
Abciximab competitively binds to the GP IIb/
/IIIa receptor and prevents binding of fibrinogen and
von Willebrand factor to activated platelets, and
therefore blocks the final common pathway for
platelet aggregation while adhesion and secretion
are preserved [16–18]. Plasma concentration of
abciximab available after an IV bolus and subse-
quent infusion is sufficient to develop effective de-
crease in platelet aggregation. In contrast to IV
administration, the IC route results in much high-
er concentrations of abciximab within the culprit
vessel, thus providing additional dose-dependent
antithrombotic, and antiinflammatory effects [16,
19–24]. Desch et al. [8] sampling blood from the
coronary sinus in STEMI patients have recently
proved that a direct IC bolus injection results in
a more pronounced local inhibition of platelet func-
tion and a higher degree of GP IIb/IIIa receptor
occupancy compared with a standard IV bolus in-
jection (median 93.5% [interquartile range 92.7–
–95.4] vs 74.0% [17.6–94.0]; p = 0.04). These data
are in agreement with the latest observations from
the ICE trial which demonstrated that IC when com-
pared with IV bolus administration of eptifibatide,
a competitive GP IIb/IIIa inhibitor, resulted in
a higher local platelet GP IIb/IIIa receptor occupan-
cy, which was associated with improved microvas-
cular perfusion in patients undergoing urgent cor-
onary stenting [25]. The difference in receptor oc-
cupancy between IC and IV administration of GP
IIb/IIIa inhibitors had been assumed but demon-
strated never before.
Marciniak et al. [20] have shown that abciximab
at lower concentrations (1.5–3.0 µg/mL) prevents
further aggregate formation, however achieving
concentrations ≥ 10 µg/mL results in an extensive
dispersion of platelet aggregates. Inhibition of plate-
let-induced thrombin generation is an additional
dose-dependent effect of abciximab resulting in
a decreased release of platelet granules containing
inhibitors of fibrinolysis such as plasminogen acti-
vator inhibitor-1 and a2-anti-plasmin [16]. High
concentrations of abciximab also inhibit thrombin-
-antithrombin complex formation, prothrombin frag-
ment F1+2 generation, platelet-derived growth
factor and platelet factor 4 release, as well as in-
corporation of thrombin into clots, and microparti-
cle formation [26].
High local concentrations of abciximab obtain-
able with IC administration may result in some non-
-GP IIb/IIIa properties which are mainly based on
complex anti-inflammatory interactions. In contrast
to other GP IIb/IIIa inhibitors, abciximab is a non-
-selective GP IIb/IIIa receptor antagonist [16, 27,
28]. Interactions of abciximab with the Mac-1 leu-
kocyte receptors and vitronectin receptors on en-
dothelial and smooth muscle cells are postulated to
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decrease the inflammatory response in the endo-
thelium of the injured vessel, hence reducing fur-
ther platelet aggregation [29–32].
All these mechanisms may play a role in reduc-
tion of reperfusion injury and a higher degree of
myocardial salvage possibly translating into im-
provement in clinical outcome in patients treated
with IC bolus of abciximab as compared with IV
administration. This, however, was not confirmed
in the recently published study evaluating the role
of IC abciximab and bivalirudin on myocardial sal-
vage and reperfusion injury in the porcine ischemia/
/reperfusion model [9]. Studied animals with myo-
cardial infarction (MI) induced by balloon occlusion
received IV bivalirudin and then five minutes prior
to reperfusion, either a coronary downstream infu-
sion of abciximab or saline. Similar size of the ne-
crotic area in both groups as evaluated by histolo-
gical assessment and biochemical marker concentra-
tions is in line with comparable left ventricular
ejection fraction (LVEF) at 48 h in abciximab- and
saline-treated animals. However, the number of
haemorrhagic infarctions detected by micro- and
macroscopic evaluation tended to be higher in the
abciximab-treated group (70 vs 20%; p = 0.07) [9].
The authors concluded that the lack of superiority
of combined treatment with IC abciximab and pe-
ripheral bivalirudin over bivalirudin unaided in
terms of myocardial salvage may be attributed to
local abciximab-induced haemorrhage [9]. The fact
that the infarct-related artery (IRA) was occluded
with a balloon, rather than by a thrombus, presents
a major limitation to this, otherwise elegant, exper-
iment as it eliminated the risk of thrombus-related
distal embolization, a key target of abciximab action
in the STEMI setting.
Clinical studies overview before
the AIDA STEMI trial
In a nonrandomized, retrospective study car-
ried out in patients (n = 397) with a broad spec-
trum of acute coronary syndromes (ACS) published
by Wohrle et al. [33] the incidence of major adverse
cardiac events (MACE) including death, MI, and
urgent revascularization was significantly lower in
patients with IC compared with IV administration
of abciximab (10.2 vs 20.2%; p < 0.008) at 30 days
of follow-up. MACE occurred significantly less of-
ten after IC abciximab as compared with the IV use
only in patients with pre-procedural TIMI 0/1 flow,
but not with TIMI 2/3 flow [33].
In a retrospective study published by Kakkar
et al. [34] in unselected patients (n = 173) under-
going coronary stenting and abciximab administra-
tion, the incidence of the 6-month composite end-
-point of death or MI was significantly lower in the
IC than in the IV bolus injection group (5.9 vs 13.9%;
p < 0.04).
Bellandi et al. [35] reported a substantial reduc-
tion in the final infarct size assessed by single pho-
ton emission tomography (13.5 ± 11.2 vs 21.4 ±
± 12.7% of left ventricle [LV]; p < 0.044), leading
to an improvement in LVEF (53.3 ± 9.5 vs 46.3 ±
± 10.7%; p < 0.035) at 1 month after pPCI with
IC vs IV abciximab administration in consecutive
patients with a first STEMI (n = 45) and pre-pro-
cedural IRA TIMI flow 0–1.
A significant improvement in coronary flow in
the culprit vessel after IC abciximab administration
(corrected TIMI frame count 48 ± 37 to 33 ± 33;
p = 0.001) but not after IV delivery was observed
by Romagnoli et al. [36] in patients with ACS un-
dergoing urgent PCI. Interestingly, the acute de-
crease in the corrected TIMI frame count after IC
bolus occurred in 37% of patients with vs 4% of
those without a visible thrombus (p = 0.008).
Galache Osuna et al. [37] found considerably
less post-procedural myocardial damage as as-
sessed by troponin I and defined as an over 5-fold
increase above the upper normal value (26 vs 51%;
p < 0.05) in patients treated with an IC bolus of
abciximab (n = 72) than in those receiving IV treat-
ment (n = 65) in the setting of ACS treated with
coronary angioplasty with stent implantation.
In the randomized LIPSIAbciximab-STEMI
study published by Thiele et al. [38] the infarct size
evaluated by magnetic resonance imaging was sig-
nificantly smaller after IC (n = 77) compared with
IV (n = 77) abciximab bolus administration. The
extent of microvascular obstruction was smaller and
ST-segment resolution was significantly more pro-
nounced in the IC abciximab group. It should be
underlined that IC vs IV abciximab bolus adminis-
tration rendered greater clinical benefit in case of
anterior MI, time from symptom onset to reperfu-
sion > 4 h, as well as impaired TIMI flow and per-
fusion grades after pPCI [38]. A tendency, not quite
reaching statistical significance, towards lower rates
of the composite MACE (cardiac deaths, nonfatal
reinfarctions, need for target vessel revasculariza-
tion (TVR), new onset congestive heart failure) at
30 days follow-up was seen after IC vs IV abciximab
administration (5.2 vs 15.6%, p = 0.06) [35]. As re-
cently reported, the advantage of the IC strategy
was maintained during long-term observation [6].
After 6 months of follow-up significantly smaller
infarct size and less cases of LV remodeling were
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observed in the IC abciximab group as compared
with the standard IV treatment. Moreover, a sig-
nificant recovery of LV function was exclusively
observed in the IC abciximab group. These benefi-
cial effects were also translated into a trend towards
a reduced MACE rate in the IC abciximab group at
6-month follow-up (10 vs 21%, p = 0.07) [6].
Furthermore, a subanalysis of the LIPSIAbcixi-
mab-STEMI study [10] revealed that the incidence
of aborted MI (≥ 50% ST-segment resolution and
a lack of subsequent cardiac enzyme rise ≥ 2-fold
the upper normal limit) was significantly higher in
the IC than IV group.
Dominguez-Rodriguez et al. [39] showed
a higher reduction in soluble CD40 ligand concen-
tration after IC bolus abciximab administration as
compared with the IV route in patients with STEMI
undergoing thrombus aspiration during pPCI. CD40
ligand (CD40L) regarded as a unique molecule link-
ing inflammation, thrombosis, and restenosis, is
secreted by circulating aggregates of platelets and
leukocytes. Soluble CD40 ligand binds to platelets
via an aIIbb3-dependent mechanism and triggers
further platelet activation. Moreover, the IC strat-
egy was associated with a significantly smaller in-
farct size when compared with IV bolus application.
Due to the limited number of patients, no signifi-
cant differences were detected in terms of clinical
outcome at 30-day follow-up [39].
A post hoc analysis of the EASY trial performed
by Bertrand et al. [40] showed no differences be-
tween patients receiving IC and IV bolus abciximab
regarding the cardiac necrosis biomarkers (creati-
ne kinase-MB, and troponin T) release or the clini-
cal outcomes after uncomplicated transradial coro-
nary stent implantation. However, it should be un-
derlined that, according to the study protocol,
STEMI patients were excluded.
A relevant improvement in myocardial reper-
fusion assessed as myocardial blush grade (MBG)
2/3 (76 vs 67%; p = 0.022) and a decrease of about
30% in the enzymatic infarct size (p = 0.008) were
observed in the CICERO trial [41] in STEMI pa-
tients randomized to IC bolus application of abcixi-
mab (n = 271) given directly after thrombectomy
compared with IV bolus administration (n = 263).
However, the rates of complete ST-segment reso-
lution (64 vs 62%; p = 0.562) were comparable be-
tween the groups. Furthermore, the study had in-
sufficient power to detect significant differences in
clinical events [41].
In the EASY-MI Study, STEMI patients who
had been referred for pPCI within 6 h of symptom
onset, were randomized to receive IC or IV abcixi-
mab bolus at a standard (0.25 mg/kg) or high dose
(≥ 0.30 mg/kg) [42]. Aspiration thrombectomy was
performed in 40% of the IC group and in 44% of
those treated with IV bolus. Neither the higher dose
nor IC abciximab bolus were associated with greater
inhibition of platelet aggregation, improved acute
or late results compared with the standard IV dos-
ing and administration [42].
In a single-site, randomized study in STEMI
patients (n = 355) undergoing pPCI Iversen et al.
[43] reported significantly better results with IC vs
IV abciximab in terms of mortality (1.1 vs 5.3%;
p = 0.02), TVR (3.8 vs 9.4%; p = 0.03) and the com-
posite end-point including all-cause death, MI and
TVR (7.6 vs 19.4%; p = 0.001) within 30 days after
randomization. Recently the authors have published
results of 1-year follow-up. Benefits of IC abciximab
administration regarding mortality (2.7 vs 10.0%;
p = 0.004), TVR (7.6 vs 14.1%; p = 0.04) and the
composite end-point (9.2 vs 20.6%; p = 0.002) were
maintained at 1 year and the difference in the rates
of MI (5.4 vs 11.8%; p = 0.03) became significant
in favour of the IC route [43].
Some of the studies mentioned above failed to
show any clinical advantage of IC administration of
abciximab over the IV route [6, 30, 33–36, 38]. How-
ever, except for the EASY and EASY-MI trials [40,
42] characterized by low risk profiles of the stud-
ied populations, all other studies demonstrated im-
provements in different surrogate end points (in-
farct size assessed with biomarkers or imaging mo-
dalities, obstruction of coronary microcirculation
evaluated by angiography or contrast-enhancement
magnetic resonance, ST-segment resolution, mark-
ers of platelet activation) related to IC as compared
with IV abciximab administration. It should be un-
derlined that data from other studies strongly sug-
gest superiority of IC over IV administration in
high-risk STEMI patients, while the relative gain
in the low risk population is questionable [5, 6, 33–
–39, 41, 43].
The bolus of abciximab is usually administered
through the guiding catheter into the IRA. However,
the use of a dedicated perfusion catheter — Clear-
Way RX Local Therapeutic Infusion Catheter
(ClearWay, Atrium Medical Corp, Hudson, NH) fa-
cilitates local drug delivery resulting in obtaining
a much higher drug concentration within the cul-
prit artery since it prevents loss of abciximab in the
aorta and a rapid wash out of the drug by the coro-
nary flow. Prati et al. [44] tested the effectiveness
of local abciximab delivery to the site of IC throm-
bus vs IC bolus infusion in patients with ACS un-
dergoing coronary angioplasty in the COCTAIL
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Study. Despite a low number of patients included
(n = 50), encouraging results were obtained: a sig-
nificantly higher reduction of thrombus (mean per-
centage change of the thrombus score: 33.8 vs 3.9%;
p = 0.002) and superior corrected TIMI frame count
(15.3 ± 10.2 vs 21.1 ± 9.9; p = 0.049) were ob-
served among patients of the local delivery group
as compared with those of the IC infusion group.
These benefits translated into significantly better
short- (procedure-related MI: 10 vs 43%; p = 0.018)
and long-term (MACE at 1 year: 5.9 vs 27.2%;
p = 0.046) clinical outcome. These results strong-
ly suggest that the use of the dedicated perfusion
catheter leads to higher concentrations of abciximab
within the thrombus, allowing for an additional anti-
platelet, antithrombotic, and antiinflammatory effect [44].
Selective IC delivery of abciximab facilitated by
the ClearWay catheter tested in the Crystal AMI
trial was safe and produced higher myocardial blush
scores (MBG of 3: 75 vs 45%) as well as a trend
towards more significant ST-segment resolution
(80 vs 70%) [45].
Meta-analyses before
the AIDA STEMI trial
The available knowledge regarding the compari-
son of the IC abciximab regimen vs the IV standard
route was summarized in six different meta-analy-
ses [11–15, 46, 47].
All trials included in these meta-analyses have
important limitations: all were carried as single-
-center studies with relatively low numbers of par-
ticipants and only some of them were randomized.
One of the meta-analyses mixed different clinical
scenarios (STEMI and non-ST-elevation ACS) [46,
47] while two others assessed various GP IIb/IIIa in-
hibitors [12, 15]. Nevertheless, all meta-analyses
provided valuable and clinically relevant information.
The meta-analysis by Hansen et al. [46] includ-
ed data from five randomized and three retrospec-
tive studies, with a total number of 2,301 patients,
including 997 with STEMI. Pooled data analysis
demonstrated significantly reduced mortality (OR
[95% CI] = 0.57 [0.35–0.94]; p = 0.028), and a trend
toward reduction of MACE (OR [95% CI] = 0.62
[0.38–1.03]; p = 0.066) during up to 12 months of
follow-up with IC vs IV abciximab. The significant
reduction of MACE after 1 month of follow-up was
exclusively limited to studies composed of STEMI
patients [46].
The aim of the meta-analysis performed by
Navarese et al. [11] and incorporating 6 randomized
trials with a total number of 1246 participants, was
to assess the clinical efficacy and safety of IC vs IV
abciximab administration in STEMI patients under-
going primary angioplasty basing exclusively on
randomized trials. At 30 days IC abciximab was as-
sociated with marked reductions in mortality (OR
[95% CI] = 0.43 [0.20–0.94]; p = 0.03) and TVR
(OR [95% CI] = 0.53 [0.29–0.99]; p = 0.05) as com-
pared with IV abciximab, but no significant differ-
ence regarding the prevalence of recurrent MI was
observed between the two strategies. Importantly,
the clinical advantages of IC abciximab treatment
were not associated with any excess of major bleed-
ing complications [11].
Friedland et al. [12] searched for randomized
studies comparing IC with IV administration of dif-
ferent GPIs (abciximab, eptifibatide, tirofiban) dur-
ing coronary angioplasty. Ten randomized studies
involving 1590 patients were included into the
meta-analysis. Seven of these studies were com-
posed only of STEMI patients while in the others
the percentage of such patients ranged from 26%
to 63%. One study examined eptifibatide, 2 others
tested tirofiban while the 7 remaining studies inves-
tigated abciximab. No difference in terms of safety
and tolerability of IC and IV administration was
observed. Patients treated with IC administration
of GP IIb/IIIa inhibitors were more likely to have
complete reperfusion (TIMIgrade 3 flow) after the
intervention (RR [95% CI] = 1.08 [1.02–1.15]). IC
administration was also associated with a significant
decrease in short-term (1 month to 3 months) TVR
(RR [95% CI] = 0.54 [0.30–0.96]) as well as in short-
-term mortality (RR [95% CI] = 0.45 [0.23–0.90]).
The difference in mortality was no longer significant
in the mid-/long-term follow-up (≥ 6 months) [12].
Three other meta-analyses comparing IC vs IV
abciximab administration in the setting of pPCI have
been published recently [13–15]. Despite differenc-
es in their design as well as the characteristics of
studies included [11–15, 46, 47], all meta-analyses
present a consistent message, showing superiority
of IC over IV administration of abciximab regard-
ing clinical outcome.
AIDA STEMI trial:
Lost battle or lost war?
Recently, long awaited results of the first multi-
center, randomized, open-label, controlled trial test-
ing whether IC abciximab bolus administration in
comparison to standard IV application improves the
clinical outcome of STEMI patients undergoing
pPCI have been published [4]. According to the
AIDA STEMI study protocol, the IC bolus delivered
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directly through the guiding catheter as well as the
IV bolus were followed by an IV infusion of abcixi-
mab for 12 h [4]. Thrombectomy was used in about
20% of patients almost equally in both groups, par-
ticularly in lesions with high thrombus burden. The
abciximab bolus was administered directly after
penetration of the culprit lesion with the guiding
wire to allow for high local concentrations of the
antithrombotic agent at the thrombus and distal
myocardium. No specific infusion balloons or per-
fusion catheters were used. The primary study end-
-point was the composite of all-cause death, rein-
farction, or new congestive heart failure within
90 days after randomization. The secondary endpoints
were defined as: time to occurrence of combined
clinical endpoint, TIMI-flow post pPCI, ST-segment
resolution, infarct size assessed by creatine kinase-
release. Safety outcome was evaluated on the ba-
sis of the occurrence of bleeding according to the
GUSTO definition and life-threatening arrhythmia
or hemodynamic compromise during the abciximab
injection. The study population consisted of 2065
patients with a suspected STEMI enrolled at
30 centers in Germany [4]. With regard to previ-
ous studies and meta-analyses results, the AIDA
STEMI trial was expected to confirm the superior-
ity of IC over IV administration in STEMI patients
treated with pPCI. The opposite was shown how-
ever (Table 1) [4]. The cumulative primary clinical
end-point did not differ between the IC and IV
groups. However, curves reflecting cumulative
event-free survival had diverging directions in
favour of the IC strategy, while after approximate-
ly 10–15 days they tended to converge. What could
possibly be the explanation of this phenomenon?
Since abciximab acts during the first hours after
administration, it can be assumed that the gain of
IC administration was obtained early after the pro-
cedure, but subsequently lost. Looking for the rea-
son of the reversal of the initially observed tenden-
cy, one may speculate that those who gained most
from IC abciximab are more prone to have cardio-
vascular events if the following antiplatelet thera-
py is insufficient. A reported tendency towards bet-
ter outcomes with IC vs IV abciximab with prasu-
grel instead of clopidogrel as the following
antiplatelet agent seems to support this hypothe-
sis. Significantly better results obtained with IC
administration of abciximab regarding the occur-
rence of heart failure are very difficult to interpret
and they may be accidental as no difference between
the compared strategies of treatment regarding the
secondary end-points was observed. Both strate-
gies were equally safe [4].
In the context of these disappointing results,
some important comments should be made. Very
low 90-days all-cause mortality (4.5 and 3.6% for IC
and IV groups, respectively) along with only mo-
destly impaired LV systolic function in most of the
study patients (a median LVEF of 50% in both arms)
Table 1. Results of the AIDA STEMI trial [4]
End point IC abciximab IV abciximab P
Efficacy
A composite of all-cause death, reinfarction, 65/935 (7.0%) 71/932 (7.6%) 0.58
new congestive heart failure at 90 days
All-cause death at 90 days 42/935 (4.5%) 34/932 (3.6%) 0.36
Reinfarction at 90 days 17/935 (1.8%) 17/932 (1.8%) 0.99
New congestive heart failure at 90 days 22/935 (2.4%) 38/935 (4.1%) 0.04
Safety
Bleedings according to the GUSTO definition at 90 days 131/985 (13.3%) 129/999 (12.9%) 0.63
Life-threatening/severe 26/985 (2.6%) 18/999 (1.8%)
Moderate 26/985 (2.6%) 26/999 (2.6%)
Mild 79/985 (8.0%)   85/999 (8.5%)
Stroke in-hospital 5/985 (0.5%) 7/999 (0.6%) 0.7
Stent thrombosis according to the ARC definition 17/985 (1.7%) 20/999 (2.0%) 0.65
Definitive 5 12
Probable 12 8
Hemodynamic compromise during abciximab bolus 1/985 (0.1%) 6/999 (0.6%) 0.06
Life-threatening arrhythmia during pPCI 17/985 (1.7%) 21/999 (2.1%) 0.22
ARC — Academic Research Consortium; IC — intracoronary; IV — intravenous; pPCI — primary percutaneous coronary intervention
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suggest that the majority of the population investi-
gated in the AIDA STEMI trial was at low risk [4]
while according to the existing data the superiority
of IC over IV abciximab administration can be ex-
pected mainly in high risk populations. Although
Thiele at al. [38] demonstrated in the LIPSIA pilot
study that the beneficial effect of IC abciximab ad-
ministration on infarct size and microvascular ob-
struction was mostly restricted to high risk subjects
(anterior STEMI, impaired epicardial blood flow
after pPCI, late hospital admission after symptom
onset), they designed the AIDA STEMI trial as an
all-comer study [4]. In our opinion, this approach
was inappropriate as a significant relationship be-
tween a patient’s risk profile and GP IIb/IIIa inhi-
bitor — dependent benefits regarding mortality has
been proven [48]. Therefore, no advantage of IC
over IV abciximab administration should be as-
sumed in low- and intermediate-risk STEMI pa-
tients where GP IIb/IIIa inhibitors do not improve
the prognosis in general.
Furthermore, despite being the largest trial
assessing clinical outcomes in patients treated with
IC abciximab, the AIDA STEMI trial seems to be
underpowered for the primary end point, as the
event rate within 90 days in the IV arm as estimat-
ed by the investigators in the sample size calcula-
tion was 12% [4]. Similarly, a 4% absolute risk re-
duction for the primary end point associated with
IC abciximab injection is probably overestimated
when considering the risk profile of the study par-
ticipants [4].
Hopefully, subgroup analyses of the trial might
provide a substantial insight into the knowledge on
subsets of patients who particularly benefit from IC
abciximab administration. Such information would
help to design future studies in this filed.
Updated meta-analysis of randomized
clinical trials comparing IC and IV
abciximab administration in STEMI
Due to the release of the AIDA STEMI trial
results [4] and extended follow-ups of other studies
[5, 6] we aimed to perform an updated meta-analy-
sis of randomized trials (RCTs) comparing the cli-
nical efficacy and safety of IC vs IV abciximab admi-
nistration in STEMI patients treated with pPCI.
The methods were previously described in
details [11]. Briefly, we conducted the present
meta-analysis according to established methods,
following the guidelines by the Cochrane Collabo-
ration [49], and the PRISMA statement for report-
ing systematic reviews and meta-analyses in health
care interventions [50]. A systematic investigation
of all published and unpublished literature includ-
ing oral presentations was performed as reported
in the introduction section, to minimize the risk of
a bias. The quality of included studies was appraised
by two unblinded reviewers. Data were abstracted
on prespecified forms by two independent investi-
gators, neither involved in any of the retrieved stud-
ies. Divergences were resolved by discussion with
a third investigator.
Citations were screened at the title/abstract
level and retrieved as full reports. The inclusion
criteria were: i) studies comparing IC vs IV admin-
istration of abciximab in ii) STEMI patients under-
going pPCI iii) RCTs. The main exclusion criteria
included: 1) absence of comparator group and
2) observational not randomized studies.
All-cause mortality was selected as the prima-
ry end point while MI, TVR and major bleeding com-
plications were the secondary end points. We per-
formed a prespecified subanalysis of RCTs released
before the AIDA STEMI trial.
Odds ratios (ORs) and 95% confidence inter-
vals (95% CI) were computed from individual stu-
dies according to the intention-to-treat principle.
Between-study heterogeneity was evaluated with
the 2 test-based Q statistic and was considered sta-
tistically significant at a level of < 0.10 [50]. Pooled
OR was calculated using a Fixed-Effect Model with
the Mantel-Haenszel method. The DerSimonian
and Laird Random Effect Model was used in case
of significant heterogeneity and/or moderate or sig-
nificant inconsistency (> 50%) across the studies.
The potential publication bias was examined by
constructing a “funnel plot”, in which sample size
was plotted against ORs [51]. In addition, a mathe-
matical estimate of asymmetry of this plot was pro-
vided by the linear regression approach [52]. Asym-
metry was considered to be present if the intercept
of the regression line deviated significantly from
zero. All analyses were conducted using Review
Manager version 5.1 (Nordic Cochrane Centre,
Cochrane Collaboration, Copenhagen, Denmark).
After a systematic search 6562 citations were
identified: 155 in the PubMed database, 206 in the
CENTRAL database, 5770 in the Google Scholar
database, and 431 in other databases. 6549 titles/
/abstracts were excluded as non-relevant. We found
13 trials fulfilling the inclusion criteria. Among them
6 studies were excluded according to explicit se-
lection criteria: absence of a comparator group
(n = 1), non-randomized studies (n = 3), duplicate
reporting (n = 1), and lack of follow-up outcome
data (n = 1). A total of seven RCTs were finally
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included in the meta-analysis (n = 3311). The total
numbers of patients were 1668 and 1643 in the IC
and IV groups, respectively. However, results of the
AIDA STEMI trial (n = 2065) include data for death
and MI and for bleeding complications only for 1867
and 1984 patients, respectively. In case of clinical
events reported within a particular study at differ-
ent time points, the longest follow-up was account-
ed for in the analysis. Durations of follow-up pe-
riods of the studies included in our meta-analysis
ranged from 1 month to 1 year with a median va-
lue of 3 months. Characteristics of the studies in-
corporated in the meta-analysis are presented
in Table 2.
Seven studies reported all-cause mortality. In
the overall cohort of patients there were a total of
120 deaths, 3.56% (56/1571) in the IC and 4.15%
(64/1542) in the IV abciximab group. There was no
evidence of publication bias as assessed by visual
inspection of the funnel plot and confirmed by lack
of significance in the Egger’s test. Since significant
heterogeneity among the included studies was
found, we applied the DerSimonian and Laird Ran-
dom Effect Model. In the overall population IC ab-
ciximab did not provide any benefits in terms of all-
cause mortality compared with IV abciximab (Fig. 1).
However, sensitivity analysis revealed that this
neutral effect was driven by the AIDA STEMI
trial, whereas data from other RCTs suggested re-
duced all-cause mortality associated with IC abcixi-
mab administration.
A total of 96 patients experienced recurrent MI.
Overall comparison indicated the superiority of IC
abciximab administration over the IV route in terms
of reduction in recurrent MI (2.5 vs 3.88%): ORFixed
[95% CI] = 0.61 [0.40–0.92]; p = 0.02 (Fig. 2). Sen-
sitivity analysis demonstrated inconsistency of ob-
tained results. After removal of the study by Ivers-
en et al. [5, 43], the difference was no longer sig-
nificant in favour of IC abciximab administration.
IC abciximab administration was comparable to
the IV route considering its impact on the occur-
rence of TVR (Fig. 3) and major bleedings (Fig. 4).
None of the studies influenced the overall results
for both end points.
It is important to be aware of the drawbacks of
our meta-analysis. If performed on individual pa-
tient’s data it would certainly provide more detailed
results, particularly by performing subgroup ana-
lyses. The inherent limitations of the studies incor-
porated into our meta-analysis include: a limited
number of enrolled patients, variability of adminis-
tration methods and various definitions of major
bleedings.
Our updated meta-analysis shows that the clini-
cal superiority of IC over IV abciximab administra-
tion in STEMI patients is no longer clear after the
release of the AIDA STEMI trial results.
New insights from the INFUSE-AMI study
A considerable variability in the penetration of
thrombectomy was observed in previously pub-
lished studies. The thrombus aspiration combined
with local administration of abciximab may exert
a synergistic effect to reduce infarct size in STEMI
patients undergoing pPCI. However, as both ap-
proaches are aimed to diminish thrombus burden,
competitive effect could not be excluded [53].
Recently results of the INFUSE-AMI trial have
been presented during the late-breaking clinical-
-trials session at the American College of Cardiolo-
gy 2012 Scientific Sessions and have been simulta-
neously published online in the “Journal of the
American Medical Association” [7]. This multi-
center, open-label, controlled, single-blind rando-
mized study tested the hypothesis that IC adminis-
tration of abciximab bolus with or without throm-
bus aspiration before stent implantation compared
with no infusion with or without thrombus aspira-
tion reduces infarct size among patients undergo-
ing pPCI for anterior STEMI who are treated with
bivalirudin [7]. Four hundred fifty two high-risk
STEMI patients with an extensive region of myo-
cardium jeopardized due to occlusion of a proximal
or mid-left anterior descending artery were en-
rolled. Subjects were randomized to one of the fol-
lowing 4 arms: (1) local IC infusion of abciximab
after thrombus aspiration, (2) local IC infusion of
abciximab, without thrombectomy, (3) thrombus
aspiration without IC abciximab, or (4) no IC abcixi-
mab and no thrombectomy. For IC administration
of 0.25-mg/kg bolus of abciximab the ClearWay RX
Local Therapeutic Infusion Catheter was used.
The primary end point of the study, infarct size
at 30 days assessed by cardiac magnetic resonance
imaging, was significantly reduced by bolus IC ab-
ciximab selectively delivered to the target area (me-
dian, 15.1%; interquartile range [IQR], 6.8–22.7%;
n = 181, vs 17.9% [IQR, 10.3–25.4%]; n = 172;
p = 0.03) but not by manual aspiration thrombecto-
my (median, 17.0% [IQR, 9.0–22.8%]; n = 174, vs
17.3% [IQR, 7.1–25.5%]; n = 179; p = 0.51) [7].
These findings confirm the usefulness of local
IC abciximab infusion through the selective deli-
very catheter. The surprising lack of benefit with
thrombus aspiration in the INFUSE-AMI trial war-
rants further investigation in large studies.
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Figure 2. Recurrent myocardial infarction in randomized clinical trials comparing intracoronary (IC) and intravenous
(IV) abciximab administration in ST-segment elevation myocardial infarction patients treated with primary percuta-
neous coronary intervention. Results are presented as odds ratio (ORs) and their confidence interval (CIs). The size of
the data markers (squares) is approximately proportional to the statistical weight of each trial; RCT — randomized
clinical trial.
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Figure 1. All-cause mortality in randomized clinical trials comparing intracoronary (IC) and intravenous (IV) abcixi-
mab administration in ST-segment elevation myocardial infarction patients treated with primary percutaneous coro-
nary intervention. Results are presented as odds ratio (ORs) and their confidence interval (CIs). The size of the data
markers (squares) is approximately proportional to the statistical weight of each trial; RCT — randomized clinical trial.
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Ongoing trials
The ongoing studies (ICAT [54], IC-Clearly
[55], TOLEDO 1 [56], EASY-RESCUE [57]) are
expected to answer several burning questions.
Nevertheless not all important questions have
still been addressed. Among high-risk patients
with ACS, the early invasive strategy with se-
lective downstream administration of GP IIb/IIIa
inhibitors is the strategy of choice, whereas biva-
lirudin should be considered in patients at high
risk for bleeding complications. Therefore, the
combination of new inhibitors of P2Y12 receptor
and bivalirudin may appear an appealing strategy
with maintained protection from ischemic events
and potentially lower risk of bleeding complica-
tions in comparison to adjunctive therapy with GP
IIb/IIIa inhibitors. The ongoing randomized trials
will hopefully provide further insights on this
issue.
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(1) Data on major bleedings available only for 30−day follow−up
(2) Data on major bleedings available only for 30−day follow−up
Figure 3. Target vessel revascularization in randomized clinical trials comparing intracoronary (IC) and intravenous
(IV) abciximab administration in ST-segment elevation myocardial infarction patients treated with primary percutane-
ous coronary intervention. Results are presented as odds ratio (ORs) and their confidence interval (CIs). The size of
the data markers (squares) is approximately proportional to the statistical weight of each trial; RCT — randomized
clinical trial.
Figure 4. Major bleedings in randomized clinical trials comparing intracoronary (IC) and intravenous (IV) abciximab
administration in segment elevation myocardial infarction patients treated with primary percutaneous coronary
intervention. Results are presented as odds ratio (ORs) and their confidence interval (CIs). The size of the data
markers (squares) is approximately proportional to the statistical weight of each trial; RCT — randomized clinical trial.
241
Jacek Kubica et al., Updated evidence on IC abciximab in STEMI
www.cardiologyjournal.org
Conclusions
The IC regimen remains an easy-to-use alter-
native to IV abciximab administration resulting in
a higher drug concentration in the target area and
potential additional dose-dependent antiplatelet,
antithrombotic, and antiinflammatory effects. How-
ever, the IC route for abciximab administration can-
not be currently recommended as the preferred
option basing on the results of the AIDA STEMI
trial and our updated meta-analysis. In our opinion,
therapy with abciximab regardless the route of ad-
ministration should be restricted to high-risk
STEMI patients, particularly these with a visible
thrombus impairing coronary blood flow. Further-
more, we believe that the negative results of the
AIDA STEMI trial are driven by inappropriate in-
clusion criteria. As these data are in conflict with
experimental studies and previous clinical trials,
conduction of another adequately powered study
enrolling exclusively high-risk participants with
a high thrombus burden and large area at risk seems
to be the only solution to finally determine the clini-
cal efficacy and safety of IC abciximab administra-
tion in the STEMI setting. In addition, other issues
that should be further addressed in future studies
include: use of IC abciximab in combination with
thrombectomy, role of selective delivery systems
when compared with abciximab administration
through the guiding catheter, necessity for a pro-
longed IV infusion of abciximab after IC bolus admini-
stration, and comparison between IC abciximab ad-
ministration and bivalirudin with concomitant treat-
ment with new inhibitors of the P2Y12 receptor.
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